Third Rock Ventures raises $616 million in fundraising drive

1 November 2016

Third Rock Ventures is to spend proceeds from its latest $616 million fundraising drive on investing in healthcare firms with a particular emphasis on innovative product engine companies in areas including oncology, immunology, neurological disorders, cardiovascular disease and rare genetic diseases.

Set up by industry veterans, the US healthcare venture firm has now raised a total of $1.9 billion in four fundraising campaigns, and its latest one, Fund IV, was significantly oversubscribed.

"We aim to be the preferred provider of innovative programs in important disease areas to address the bio-pharma industry’s pipeline needs"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK